Provectus Biopharmaceuticals, Inc.
PVCT
$0.0841
-$0.0037-4.21%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -4.76M | -3.03M | -2.79M | -2.78M | -3.10M |
| Total Depreciation and Amortization | 7.10K | 8.80K | 8.80K | 8.80K | 8.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.33M | 46.80K | 49.10K | 48.50K | 48.00K |
| Change in Net Operating Assets | 142.80K | 39.70K | -405.00K | -271.50K | 472.80K |
| Cash from Operations | -3.28M | -2.93M | -3.14M | -2.99M | -2.57M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 3.15M | 2.55M | 2.79M | 2.84M | 2.48M |
| Total Debt Repaid | -405.10K | -391.90K | -398.40K | -386.00K | -283.40K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.75M | 2.16M | 2.39M | 2.46M | 2.19M |
| Foreign Exchange rate Adjustments | -800.00 | -23.60K | -22.00K | -23.20K | -24.40K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -537.10K | -796.00K | -769.90K | -558.70K | -405.00K |